论文部分内容阅读
目的探讨重组人促红细胞生成素治疗慢性心力衰竭患者的临床效果。方法选取2013年1月至2015年2月沈阳市第四人民医院收治的126例慢性心力衰竭患者为研究对象,按随机数字表法将其分为观察组与对照组,各63例。对照组患者给予常规抗心力衰竭治疗,观察组患者在对照组基础上给予皮下注射重组人促红素注射液进行治疗,比较两组患者治疗效果。结果治疗后,观察组患者的血红蛋白和红细胞比容均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应发生率明显低于对照组,差异有统计学意义(χ2=3.88,P<0.05);治疗后,观察组患者的收缩压、舒张压、心率均明显低于对照组,差异均有统计学意义(均P<0.05)。结论采用重组人促红细胞生成素治疗慢性心力衰竭临床疗效显著,不仅可以有效提升患者血红蛋白浓度和红细胞比容,改善血流动力学,还可有效减少不良反应发生,安全性较高。
Objective To investigate the clinical effect of recombinant human erythropoietin on patients with chronic heart failure. Methods A total of 126 patients with chronic heart failure admitted to the Fourth People’s Hospital of Shenyang from January 2013 to February 2015 were selected as study subjects and divided into observation group and control group according to the random number table method, with 63 cases in each group. Patients in the control group were given conventional anti-heart failure treatment. Patients in the observation group were given subcutaneous injection of recombinant human erythropoietin injection on the basis of the control group, and the treatment effect was compared between the two groups. Results After treatment, the hemoglobin and hematocrit of the observation group were significantly higher than those of the control group (all P <0.05); the total effective rate of the treatment group was significantly higher than that of the control group (Χ2 = 3.88, P <0.05). After treatment, the incidence of adverse reactions in the observation group was significantly lower than that in the control group (χ2 = 3.88, P <0.05) Heart rate were significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of recombinant human erythropoietin in the treatment of chronic heart failure is significant. It can not only effectively improve hemoglobin concentration and hematocrit in patients, improve hemodynamics, but also reduce adverse reactions and have higher safety.